| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA5244147 | B | Inhibition of MALT-1 mediated CYLD cleavage in PMA/ionomycin stimulated human Jurkat T cells assessed as decrease in Frag-CYLD level by Western blot analysis | Homo sapiens | 1 | ALA5241134 | cell-based format | Scientific Literature | |
| 2. | ALA5244148 | A | Metabolic stability in human liver microsomes assessed as intrinsic clearance | Homo sapiens | 30 | ALA5241134 | microsome format | Scientific Literature | |
| 3. | ALA5244149 | F | Inhibition of IL-2 production in PMA/ionomycin stimulated human Jurkat T cells | Homo sapiens | 30 | ALA5241134 | cell-based format | Scientific Literature | |
| 4. | ALA5244150 | A | Metabolic stability in mouse liver microsomes assessed as intrinsic clearance | Mus musculus | 30 | ALA5241134 | microsome format | Scientific Literature | |
| 5. | ALA5244151 | B | Inhibition of MALT1 (unknown origin) | Homo sapiens | 42 | ALA5241134 | single protein format | Scientific Literature | |
| 6. | ALA5244152 | A | Apparent permeability of the compound in human Caco-2 cells | Homo sapiens | 1 | ALA5241134 | cell-based format | Scientific Literature | |
| 7. | ALA5244153 | A | Drug concentration in BALB/cAnNCrlCr mouse at 1 mg/kg, iv administered as single dose | Mus musculus | 1 | ALA5241134 | organism-based format | Scientific Literature | |
| 8. | ALA5244154 | A | AUC (0 to infinity) in BALB/cAnNCrlCr mouse at 1 mg/kg, iv administered as single dose | Mus musculus | 1 | ALA5241134 | organism-based format | Scientific Literature | |
| 9. | ALA5244155 | A | Half-life in BALB/cAnNCrlCr mouse at 1 mg/kg, iv administered as single dose | Mus musculus | 1 | ALA5241134 | organism-based format | Scientific Literature | |
| 10. | ALA5244156 | A | Total clearance in BALB/cAnNCrlCr mouse at 1 mg/kg, iv administered as single dose | Mus musculus | 1 | ALA5241134 | organism-based format | Scientific Literature | |
| 11. | ALA5244157 | A | Cmax in BALB/cAnNCrlCr mouse at 2 mg/kg, po administered as single dose | Mus musculus | 1 | ALA5241134 | organism-based format | Scientific Literature | |
| 12. | ALA5244158 | A | AUC (0 to infinity) in BALB/cAnNCrlCr mouse at 2 mg/kg, po administered as single dose | Mus musculus | 1 | ALA5241134 | organism-based format | Scientific Literature | |
| 13. | ALA5244159 | A | Half-life in BALB/cAnNCrlCr mouse at 2 mg/kg, po administered as single dose | Mus musculus | 1 | ALA5241134 | organism-based format | Scientific Literature | |
| 14. | ALA5244160 | A | Tmax in BALB/cAnNCrlCr mouse at 2 mg/kg, po administered as single dose | Mus musculus | 1 | ALA5241134 | organism-based format | Scientific Literature | |
| 15. | ALA5244161 | A | Oral bioavailability in BALB/cAnNCrlCr mouse at 2 mg/kg administered as single dose | Mus musculus | 1 | ALA5241134 | organism-based format | Scientific Literature | |
| 16. | ALA5244162 | F | Anti-psoriatic activity in imiquimod-induced BALB/c mouse model assessed as improvement in ear thickness administered orally twice daily for 2 days from day 7 to 9 | Mus musculus | 1 | ALA5241134 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!